Interventional × Lung Diseases × Clear all
NCT03899792 2026-01-06

LIBRETTO-121

Eli Lilly and Company

Phase 1/2 Active not recruiting
36 enrolled 13 charts 2 FDA
NCT03157128 2025-10-20

LIBRETTO-001

Eli Lilly and Company

Phase 1/2 Active not recruiting
857 enrolled 3 FDA
NCT07162883 2025-09-09

Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)

Qilu Pharmaceutical Co., Ltd.

Phase 3 Not yet recruiting
122 enrolled
NCT03093116 2025-07-10

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 2 FDA
NCT03037385 2025-05-31

ARROW

Hoffmann-La Roche

Phase 1/2 Completed
590 enrolled 58 charts 5 FDA
NCT04774952 2025-04-15

Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

Revolution Medicines, Inc.

Phase 1 Completed
58 enrolled
NCT05297734 2025-03-19

Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

Stanford University

Phase NA Recruiting
2,996 enrolled
NCT05462717 2024-11-07

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Revolution Medicines, Inc.

Phase 1 Active not recruiting
222 enrolled